Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Form 13F-HR CANTOR FITZGERALD, L. For: Jun 30
-
Form 13F-NT Cantor Fitzgerald Europe For: Jun 30
-
Kimball Electronics (KE) PT Raised to $27 at Cantor Fitzgerald
-
Merlin to go public via SPAC merger valued at $800 million
-
Merlin to Go Public via Business Combination with Inflection Point-led SPAC as Leading Defense Prime Contractor for AI in Aviation
-
Cantor Fitzgerald Reiterates Overweight Rating on Alumis Inc (ALMS)
-
Cantor Fitzgerald Reiterates Overweight Rating on Codexis, Inc. (CDXS)
-
Cantor Fitzgerald Reiterates Overweight Rating on Aardvark Therapeutics Inc (AARD)
-
Cantor Fitzgerald Reiterates Overweight Rating on United Therapeutics Corp. (UTHR)
-
Eve raises $230 million through equity offering and Brazil listing
-
Eve Announces $230 Million Equity Capital Raise and Dual Listing in the United States and Brazil
-
Cantor Fitzgerald Starts Workday (WDAY) at Overweight
-
Cantor Fitzgerald Starts Paycom Software (PAYC) at Neutral
-
Cantor Fitzgerald Starts Paylocity Holding (PCTY) at Overweight
-
Robinhood Markets (HOOD) PT Raised to $128 at Cantor Fitzgerald, 'a must-own name', 'Record Month for HOOD'
-
EnviroGold Global Retains Cantor Fitzgerald as Financial Advisor
-
Aquestive Therapeutics prices $85 million stock offering
-
Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock
-
Form 10-Q Cantor Fitzgerald Income For: Jun 30
-
Aquestive secures $75 million funding from RTW for Anaphylm launch
-
Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film
-
Orchid Island Capital Announces August 2025 Monthly Dividend and July 31, 2025 RMBS Portfolio Characteristics
-
Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-
AleraCare and PURE Healthcare Announce Intent to Merge
-
Rigetti Computing Inc. (RGTI) PT Raised to $18 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on Meta Platforms Inc. (META)
-
Cantor Fitzgerald Reiterates Neutral Rating on Alphabet (GOOGL)
-
Cantor Fitzgerald Reiterates Overweight Rating on SailPoint Technologies Holdings (SAIL)
-
Cantor Fitzgerald Reiterates Overweight Rating on Rubrik Inc (RBRK)
-
Cantor Fitzgerald Reiterates Overweight Rating on Regeneron Pharma (REGN)
-
Cantor Fitzgerald Reiterates Neutral Rating on Pfizer (PFE)
-
Cantor Fitzgerald Reiterates Overweight Rating on Gilead Sciences (GILD)
-
Cantor Fitzgerald Reiterates Neutral Rating on Amgen (AMGN)
-
Bristol-Myers Squibb Co. (BMY) PT Lowered to $45 at Cantor Fitzgerald
-
Abbvie (ABBV) PT Raised to $215 at Cantor Fitzgerald
-
Eli Lilly (LLY) PT Lowered to $825 at Cantor Fitzgerald
-
Cantor Fitzgerald Starts BridgeBio Oncology Therapeutics, In (BBOT) at Overweight
-
Cantor Fitzgerald Starts Almonty Industries (ALM) at Overweight
-
Form DEF 14A CANTOR FITZGERALD INFRAS For: Aug 12
-
Cantor Fitzgerald Reiterates Overweight Rating on Micron Technology (MU)
-
BigBear.ai Holdings (BBAI) PT Raised to $6 at Cantor Fitzgerald
-
Ouster Inc. (OUST) PT Raised to $30 at Cantor Fitzgerald
-
USA Rare Earth Inc (USAR) PT Raised to $20 at Cantor Fitzgerald
-
Cantor Fitzgerald Reiterates Overweight Rating on GitLab Inc (GTLB)
-
Cantor Fitzgerald Reiterates Overweight Rating on SentinelOne Inc (S)
-
Cantor Fitzgerald Reiterates Overweight Rating on Serve Robotics (SERV)
-
Cantor Fitzgerald Reiterates Overweight Rating on Archer Aviation Inc. (ACHR)
-
BitMine increases at-the-market offering to $24.5 billion
-
YieldMax ETFs Names Mike Khouw as YieldMax Strategist
-
Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
